^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    DRP®-Ixempra

    Company:
    Allarity Therap
    Type:
    Laboratory Developed Test
    Related tests:

    Details

    Evidence
    News
    DRP®-IXEMPRA® is a CDx, a complex transcriptomic signature comprising multiple mRNA biomarkers of drug response/resistance. Patients were assigned a DRP®-score, and those with scores above 67% were selected for treatment with IXEMPRA®. The DRP®-IXEMPRA® CDx is a transcriptomic signature comprising 191 mRNA biomarkers that are collectively predictive of tumor sensitivity or resistance to IXEMPRA®. Using the DRP® CDx to select likely responder patients while excluding likely resistant ones.
    Cancer:
    Breast Cancer
    Drug:
    Ixempra (ixabepilone)